BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Mechanism of Action
Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress.
Dosage Overview
Dose Range
25 mcg – 100 mcg
Route
subcutaneous
Frequency
1x daily
Cycle Length
1–4 weeks
Reconstitution
Typical Dosage (Research)
Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure.
Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically.
Considerations for Men & Women
Women: B-type natriuretic peptide. Women typically have higher baseline BNP levels than men, which is important for diagnostic cutoffs. Nesiritide (synthetic BNP) is used identically in both sexes for acute heart failure.
Men: Lower baseline BNP than women. Same clinical applications. Sex-specific diagnostic thresholds exist for BNP as a heart failure biomarker.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 1,000 mcg/ml
Volume to inject: 0.03 ml
Syringe units (U-100): 2.5 units
Pre-filled with BNP (B-type Natriuretic Peptide) defaults. Adjust values as needed.
Side Effects & Risks
Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients.
Controversial efficacy data. Concerns about renal effects and mortality in some studies led to reduced use. Requires careful hemodynamic monitoring.
Who Uses BNP (B-type Natriuretic Peptide)
Acute heart failure patients in hospital settings, cardiovascular researchers.
Frequently Asked Questions
Similar Peptides
View All Alternatives →Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
Alpha-defensins are small cationic peptides that are key components of the innate immune system. They have broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses.
Cortexin is a polypeptide complex derived from pig brain cortex, used clinically in Russia and Eastern Europe for neurological conditions including stroke recovery, traumatic brain injury, and cognitive decline.
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.